Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,262.56 89.32 0.55%
S&P 500 1,842.98 12.37 0.68%
NASDAQ 4,034.16 11.47 0.29%
Ticker Volume Price Price Delta
STOXX 50 3,119.45 27.93 0.90%
FTSE 100 6,560.45 18.84 0.29%
DAX 9,235.96 62.25 0.68%
Ticker Volume Price Price Delta
NIKKEI 14,417.68 420.87 3.01%
TOPIX 1,166.55 30.46 2.68%
HANG SENG 22,696.01 24.75 0.11%

Essilor : Disclosure of Share Capital and Voting Rights Outstanding as of January 31, 2014



  Essilor : Disclosure of Share Capital and Voting Rights Outstanding as of
  January 31, 2014

  (Pursuant to Article L.233-8 II of the French Commercial Code and articles
   221-1 and 223-16 of the General Regulations of the Autorité des Marchés
                                 Financiers)

Business Wire

CHARENTON-LE-PONT, France -- February 5, 2014

Regulatory News :

As of January 31, 2014, shares and voting rights outstanding of Essilor
(Paris:EI), the world leader in ophthalmic optics, broke down as follows:

                                                              January 31, 2014
Shares outstanding                                            214,752,704
Exercisable voting rights                                     226,852,045
Total voting rights, based on all outstanding shares,         231,306,136
including shares stripped of their voting rights*

(*) Shares held by the Company.

About Essilor
The world’s leading ophthalmic optics company, Essilor designs, manufactures
and markets a wide range of lenses to improve and protect eyesight. Its
corporate mission is to enable everyone around the world to access lenses that
meet his or her unique vision requirements. To support this mission, the
Company allocates more than €150 million to research and innovation every
year, in a commitment to continuously bring new, more effective products to
market. Essilor’s flagship brands are Varilux^®, Crizal^®, Definity^®,
Xperio^®, Optifog™ and Foster Grant^®. It also develops and markets equipment,
instruments and services for eyecare professionals.
Essilor reported consolidated revenue of more than €5 billion in 2013 and
employs more than 50,000 people. It operates in some 100 countries with 22
plants, more than 400 prescription laboratories and edging facilities, as well
as several research and development centers around the world.
For more information, please visit www.essilor.com.
The Essilor share trades on the NYSE Euronext Paris market and is included in
the Euro Stoxx 50 and CAC 40 indices.
Codes and symbols: ISIN: FR0000121667; Reuters: ESSI.PA; Bloomberg: EI:FP

Contact:

Essilor
Investor Relations and Financial Communications
Phone: +33 (0)1 49 77 42 16
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement